EXPRESSF+
Live / Registered — Registered and renewed (as of 16 Dec 2021)
What this means for you
Registered since 20 Jun 2000. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 20 Jun 2020).
Record
- Serial number
- 75684834
- Registration number
- 2359863
- Mark type
- Word mark
- Filed
- 19 Apr 1999
- Published for opposition
- 28 Mar 2000
- Registered
- 20 Jun 2000
- Next maintenance due
- 20 Jun 2020
- Attorney of record
- Karen Lim
Goods and services
- Class 001 — Chemicals: Cell lines for use in the production of recombinant proteins for medical and clinical use and cells for medical or clinical use, including an insect line, a baculovirus-suspectible insect cell line, and a spodoptera frugiperda cell line having one or more of the following characteristics - cells which are genetically and morphologically distinct from the parent of Sf9 cells, cells which replicate in serum-free medium, cells which grow as a suspension of single cells without significant clumping, cells which grow exponentially with a cell doubling time of 18 to 24 hours, cells which can be passed continuously for at least 6 months while maintaining a high level of viability (>98%), cells which are highly permissive to infection with californica npv baculoviruses resulting in high-titered virus stocks, cells which are useful for the production of recombinant DNA gene cell products following infection with baculovirus vectors, cells which are useful for the production and plaque-isolation of genetically engineered baculovirus cells which meet the general identity and safety requirements for cells set by government regulatory agencies, and cells which are suitable for the manufacture of biological pharmaceutical products following cGMP standards
- Class 005 — Pharmaceuticals: Cell lines for use in the production of recombinant proteins for scientific, laboratory and medical research and cells for research of a scientific, laboratory or medical nature, including an insect line, a baculovirus-suspectible insect cell line, and a spodoptera frugiperda cell line having one or more of the following characteristics - cells which are genetically and morphologically distinct from the parent Sf9 cells, cells which replicate in serum-free medium, cells which grow as a suspension of single cells without significant clumping, cells which grow exponentially with a cell doubling time of 18 to 24 hours, cells which can be passed continuously for at least 6 months while maintaining a high level of viability (>98%), cells which are highly permissive to infection with californica npv baculoviruses resulting in high-titered virus stocks, cells which are useful for the production of recombinant DNA gene cell products following infection with baculovirus vectors, cells which are useful for the production and plaque-isolation of genetically engineered baculovirus cells which meet the general identity and safety requirements for cells set by government regulatory agencies, and cells which are suitable for the manufacture of biological pharmaceutical products following cGMP standards
Owner
- PROTEIN SCIENCES CORPORATION, Meriden, CT, US
- PROTEIN SCIENCES CORPORATION, Meriden, CT, US
- PROTEIN SCIENCES CORPORATION, Meriden, CT, US
Prosecution history
- 16 Dec 2021 — NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
- 16 Dec 2021 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 16 Dec 2021 — REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)
- 16 Dec 2021 — REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
- 05 Dec 2021 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 03 Dec 2021 — PETITION TO DIRECTOR GRANTED
- 30 Nov 2021 — ASSIGNED TO PETITION STAFF
- 21 Apr 2021 — TEAS PETITION TO DIRECTOR RECEIVED
- 01 Apr 2021 — POST REGISTRATION ACTION MAILED - SEC. 8 & 9
- 25 Jan 2021 — TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
- 15 Oct 2020 — POST REGISTRATION ACTION MAILED - SEC. 8 & 9
- 30 Sept 2020 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 20 Aug 2020 — TEAS SECTION 8 & 9 RECEIVED
- 08 Jan 2020 — REVIEW OF CORRESPONDENCE COMPLETE - ADDRESS UPDATED
- 10 Dec 2019 — CORRESPONDENCE RECEIVED IN LAW OFFICE